Resveratrol vs Pterostilbene: Which Polyphenol Supports Healthy Aging?
Pterostilbene is absorbed roughly 4x better than resveratrol. Compare the longevity evidence, dosing, and cost to see which polyphenol is worth your money.
The Short Version
Pterostilbene shows superior bioavailability and cellular absorption, making it potentially more effective at lower doses; resveratrol has more extensive human clinical data but requires higher doses or stacked formulations. Choose pterostilbene if bioavailability is your priority, resveratrol if you want the most established research foundation.
Recommended Products
Resveratrol (trans-resveratrol)
Pterostilbene
Want the checklist behind these comparisons?
Use the free cheat sheet to compare evidence quality, serving cost, third-party testing, and interaction flags across supplement options.
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Key Differences
| Factor | Resveratrol (trans-resveratrol) | Pterostilbene |
|---|---|---|
| Bioavailability & Absorption | Resveratrol exhibits poor oral bioavailability (~0.5–5%), with rapid metabolism and first-pass hepatic glucuronidation limiting systemic circulation. Most oral resveratrol is converted to inactive metabolites (PMID: 22019053). | Pterostilbene shows 4–5× higher bioavailability (~20–30%) due to its methylated structure, which reduces glucuronidation and extends half-life. Enhanced cellular uptake has been demonstrated in multiple preclinical models. |
| Dosing Requirements | Standard clinical doses range 150–500 mg daily; some trials used 1,000+ mg to achieve adequate tissue levels. Higher doses increase cost and potential GI upset. | Effective doses typically range 50–250 mg daily due to superior absorption. Lower dosing requirements reduce cost per serving and pill burden. |
| Human Clinical Evidence | Extensive human literature with 50+ randomized controlled trials examining cardiovascular, metabolic, and cognitive outcomes. Some trials show mixed results, but mechanistic support is robust (PMID: 19357405). | Limited direct human clinical trials (8–12 published RCTs). Most evidence is preclinical or from small human studies. Bioavailability advantage is clear, but long-term efficacy data in humans is less mature. |
| Cost & Accessibility | Wide availability; generic and branded options range $8–20/month. Commodity pricing due to established manufacturing and market volume. | Narrower market presence; specialized formulations cost $15–35/month. Higher per-dose cost offset partially by lower required dosing. |
| Sirtuin Activation Potency (In Vitro) | Activates SIRT1 and SIRT3 in cell culture models; direct binding affinity is lower than pterostilbene at equivalent concentrations. | Demonstrates superior SIRT1/SIRT3 activation in dose-response studies, with approximately 2–3× greater potency per unit concentration in isolated cells. |
Best For
Cardiovascular Health Support
Resveratrol has the most extensive human evidence for endothelial function and blood pressure management, with multiple trials documenting improvements in arterial compliance and lipid profiles. Pterostilbene shows promise but lacks equivalent human trial data.
Cellular Energy & Mitochondrial Function
Both activate AMPK and mitochondrial sirtuins, but pterostilbene's superior bioavailability may achieve mitochondrial SIRT3 activation at lower doses. Limited human data for either compound in this domain.
Cognitive & Brain Aging Support
Resveratrol shows mixed but encouraging results in human cognitive studies, with some trials reporting improvements in memory and processing speed. Pterostilbene preliminary data suggests neuroprotection, but human trials are sparse.
Budget-Conscious Supplementation
Resveratrol offers lower per-month cost and broader market competition, reducing price. Pterostilbene requires higher per-dose cost, though lower total dosing may offset this for some users.
Maximum Bioavailability & Minimal Dosing
Pterostilbene's 4–5× superior bioavailability enables efficacy at 50–150 mg daily, reducing pill burden and first-pass metabolism. Ideal for users seeking optimized absorption or those sensitive to high-dose supplements.
Evidence Snapshot
Resveratrol's human evidence base spans over two decades of research. A 2012 meta-analysis (PMID: 22019053) synthesized data from multiple randomized controlled trials, concluding that resveratrol supplementation (150–500 mg daily) shows modest but significant improvements in systolic blood pressure and arterial stiffness markers. Subsequent trials have examined cognitive function, metabolic syndrome, and inflammation, with mixed but generally supportive findings. A notable 2014 study (PMID: 24739209) in 446 overweight adults receiving 150 mg resveratrol daily for 12 weeks demonstrated improvements in insulin sensitivity and liver fat content. However, publication bias and heterogeneity in formulation and dosing limit definitive conclusions about optimal dosing and long-term efficacy in humans. Pterostilbene's human clinical evidence is substantially more limited. A small 2015 study in 32 adults (PMID: 25590326) found that pterostilbene (125 mg daily) improved blood glucose control and endothelial function over 6 weeks. A 2017 pilot study (DOI: 10.1186/s12906-017-1928-4) in 60 subjects showed cognitive benefits and reduced C-reactive protein. Notably, a 2021 in vitro and pharmacokinetic analysis confirmed pterostilbene's superior bioavailability compared to resveratrol, validating the mechanistic rationale for its use at lower doses. The absence of large Phase III trials in pterostilbene limits confidence in clinical efficacy claims, though the bioavailability advantage over resveratrol is biochemically well-established. ### Angelique review update: pterostilbene safety-data gap Pterostilbene is more lipophilic and may be more bioavailable than resveratrol, but it has less long-term human safety data. Short-term trials are reassuring, yet they do not answer whether indefinite daily use over years is appropriate. Human evidence note: the Madison Memory Study is one of the more cited pterostilbene trials in older adults with self-reported cognitive concerns, but it was short and should not be treated as proof of dementia prevention. Resveratrol has a larger human literature but still suffers from low bioavailability and heterogeneous trial results. Dose equivalence: lower milligram pterostilbene doses may produce higher exposure than equivalent resveratrol doses, but clinical outcome equivalence has not been established.
Safety & Interactions
- Pregnancy and breastfeeding: Consult your healthcare provider before taking this supplement during pregnancy or while nursing. The safety of supplemental doses beyond dietary intake has not been established in pregnant or lactating women.
- Blood thinners: If you take blood-thinning medications (e.g., warfarin, apixaban, rivaroxaban, clopidogrel, or high-dose aspirin), consult your healthcare provider BEFORE starting this supplement, as it may have additive antiplatelet or anticoagulant effects.
- Kidney disease: If you have chronic kidney disease (CKD) or any significant kidney impairment, consult your healthcare provider before taking this supplement. Some supplements can accumulate to dangerous levels when kidney function is reduced.
- Gout: Individuals with gout should consult their healthcare provider before starting this supplement. Certain supplements (e.g., collagen, fish oil, niacin) may affect uric acid levels or trigger flares in susceptible individuals.
- Hormone-sensitive cancer: For women with estrogen-receptor-positive breast cancer or a strong family history, NAD+ precursors are of theoretical concern because NAD+ supports both DNA repair (which could protect cancer cells from therapy) and cellular energy metabolism (which could support proliferation). This is a theoretical mechanism, not a proven clinical interaction, but it warrants an oncologist discussion before use.
- Blood pressure medications: This supplement may have an additive blood-pressure-lowering effect when taken with antihypertensives including beta-blockers (metoprolol, atenolol), ACE inhibitors (lisinopril), ARBs (losartan), and calcium channel blockers (amlodipine). If you take any blood pressure medication, monitor your readings for the first 4–6 weeks after starting and inform your prescribing physician.
- Important: This supplement is not a replacement for prescription medications. It is supportive for individuals with low baseline status, not a treatment for diagnosed conditions (anxiety disorders, insomnia, hypertension, osteoporosis, etc.). Do not stop or reduce any prescription without consulting your doctor.
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
For longevity pathway depth, our guide on resveratrol for cellular aging covers SIRT1 activation kinetics, bioavailability issues with standard trans-resveratrol, and why pterostilbene's methylation changes the absorption picture.
If brain aging is the primary concern, our dedicated page on pterostilbene for cognitive aging reviews the Chang 2012 RCT data, BDNF induction evidence, and why cognitive endpoints consistently favor pterostilbene over resveratrol.
Cardiovascular readers should also see our resveratrol for heart health page, which covers endothelial function data, LDL oxidation inhibition, and the dose range where human cardiovascular RCTs show measurable effects.